financing

News

AI specialist Chai Discovery raises $400m

Fresh from an alliance with Novartis, Chai Discovery has raised $400 million in third-round funding for its AI-based molecular design platform.

News

New biotech Avere plots listing via NextCure merger

New biotech Avere has taken a fast-track to becoming a listed company by merging with NextCure and raising $305m for an oral IL-23 drug for psoriasis.

News

Spero snaps up Innovent immunology drug in strategic pivot

Spero has licensed rights to an anti-CD40L antibody developed by China's Innovent, in a $1.1bn deal that signals a shift away from antimicrobial R&D.

News

Bayer gets €3bn from Apollo for contraceptives unit stake

Bayer has partnered with private equity group Apollo to set up a new entity that will handle its long-acting contraceptives products.

News

Kalohexis chief executive Russell Potterfield

Obesity biotech Kalohexis files confidential IPO

Just weeks after forming as a spinout from Endevica Bio, obesity drug developer Kalohexis has filed for an IPO.

News

Scribe Therapeutics joins the IPO queue

Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq as it advances its spin on CRISPR-based therapeutics.

AI specialist Chai Discovery raises $400m

New biotech Avere plots listing via NextCure merger

Spero snaps up Innovent immunology drug in strategic pivot

Bayer gets €3bn from Apollo for contraceptives unit stake

Obesity biotech Kalohexis files confidential IPO

Scribe Therapeutics joins the IPO queue

CHMP backs Novo's haemophilia A drug Frehemgo

Discover a new era of healthcare panel engagement: Grounded ...

financing

Editor's Picks